Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAG4SX)

Drug Name

BILR-355 Drug Info

Synonyms

BILR-355-BS; 11-Ethyl-5-methyl-8-[2-(1-oxidoquinolin-4-yloxy)ethyl]-6,11-dihydro-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Human immunodeficiency virus Reverse transcriptase (HIV RT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[4]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[5]
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[6]
Tenofovir	DM1IS6U	Human immunodeficiency virus infection	1C62	Approved	[4]
Lamivudine	DMI347A	Chronic HBV infection	1E51.0Z	Approved	[7]
Abacavir	DMMN36E	Human immunodeficiency virus infection	1C62	Approved	[8]
Delavirdine	DM3NF5G	Human immunodeficiency virus infection	1C62	Approved	[7]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[7]
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[9]
Etravirine	DMGV8QU	Human immunodeficiency virus-1 infection	1C62	Approved	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Reverse transcriptase (HIV RT)	TT84ETX	POL_HV1B1	Inhibitor	[2] , [3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00294372) Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients. U.S. National Institutes of Health.
2	Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. J Clin Pharm Ther. 2012 Feb;37(1):81-8.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
5	HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
6	A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
9	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
10	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.